Abstract:Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous group of mostly incurable hematologic malignancies driven by transformed stem cells (leukemic stem cells, LSC) endowed with enhanced self-renewal capacity and blocked myeloid differentiation. Insights into pathways of LSC maintenance will provide key targets for curative therapies. We have previously shown that chaperone-mediated autophagy (CMA) is essential for metabolic adaptation in HSC to regenerative stress (Dong et al., Nature 2021). To test the relevance of CMA in LSC, we developed new mouse models of AML with concomitant CMA deficiency through conditionally deleting (Vav-iCre driven) Lysosome-associated membrane protein 2 (Lamp2a, L2A) which is specific and rate-limiting for this autophagy pathway. We characterized self-renewal and myeloid differentiation potential of leukemia cells upon L2A deletion by gold-standard serial ex vivo colony assays and in vivo bone marrow transplantation assays. Our data thus far have revealed that CMA blockade causes compromised ex vivo self-renewal of LSC and significantly prolongs survival of recipients upon adoptive cell transfer compared to L2AWT controls, consistent with compromised LSC maintenance. Moreover, CMA deficient LSC presented with significantly increased myeloid differentiation compared to CMA competent LSC, suggesting that CMA impacts molecular pathways that favor self-renewal over differentiation commitment. We are currently building precise humanized models and employ degron-mediated ablation of L2A to test the consequences of CMA ablation in human AML. If successful, our study will provide exciting preclinical rationales for the testing of CMA inhibitors for eradication of LSC, particularly alongside current mainstay therapies, as a novel and potential curative option for patients with myeloid malignancies. Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous group of mostly incurable hematologic malignancies driven by transformed stem cells (leukemic stem cells, LSC) endowed with enhanced self-renewal capacity and blocked myeloid differentiation. Insights into pathways of LSC maintenance will provide key targets for curative therapies. We have previously shown that chaperone-mediated autophagy (CMA) is essential for metabolic adaptation in HSC to regenerative stress (Dong et al., Nature 2021). To test the relevance of CMA in LSC, we developed new mouse models of AML with concomitant CMA deficiency through conditionally deleting (Vav-iCre driven) Lysosome-associated membrane protein 2 (Lamp2a, L2A) which is specific and rate-limiting for this autophagy pathway. We characterized self-renewal and myeloid differentiation potential of leukemia cells upon L2A deletion by gold-standard serial ex vivo colony assays and in vivo bone marrow transplantation assays. Our data thus far have revealed that CMA blockade causes compromised ex vivo self-renewal of LSC and significantly prolongs survival of recipients upon adoptive cell transfer compared to L2AWT controls, consistent with compromised LSC maintenance. Moreover, CMA deficient LSC presented with significantly increased myeloid differentiation compared to CMA competent LSC, suggesting that CMA impacts molecular pathways that favor self-renewal over differentiation commitment. We are currently building precise humanized models and employ degron-mediated ablation of L2A to test the consequences of CMA ablation in human AML. If successful, our study will provide exciting preclinical rationales for the testing of CMA inhibitors for eradication of LSC, particularly alongside current mainstay therapies, as a novel and potential curative option for patients with myeloid malignancies.

Loss of chaperone-mediated autophagy is associated with low vertebral cancellous bone mass

Loss of chaperone-mediated autophagy does not alter age-related bone loss in male mice

Chaperone‐mediated autophagy protects the bone formation from excessive inflammation through <scp>PI3K/AKT/GSK3β</scp>/β‐catenin pathway

Chaperone‐mediated autophagy protects the bone formation from excessive inflammation through PI3K/AKT/GSK3β/β‐catenin pathway

Deletion of the Auxiliary α2δ1 Voltage Sensitive Calcium Channel Subunit in Osteocytes and Late-Stage Osteoblasts Impairs Femur Strength and Load-Induced Bone Formation in Male Mice

Osteocyte-Derived CaMKK2 Regulates Osteoclasts and Bone Mass in a Sex-Dependent Manner through Secreted Calpastatin

Low-density lipoprotein receptor deficiency reduced bone mass in mice via the c-fos/NFATc1 pathway

RETRACTED: Crosstalk between adipocytes and M2 macrophages compensates for osteopenic phenotype in the <i>Lrp5</i>-deficient mice (Retracted Article)

Loss of BMP Signaling Through BMPR1A in Osteoblasts Leads to Greater Collagen Cross-Link Maturation and Material-Level Mechanical Properties in Mouse Femoral Trabecular Compartments

Missense Mutations in LRP5 Associated with High Bone Mass Protect the Mouse Skeleton from Disuse- and Ovariectomy-Induced Osteopenia

Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function

Conditional loss of CaMKK2 in Osterix-positive osteoprogenitors enhances osteoblast function in a sex-divergent manner

Male Lrp5A214V mice maintain high bone mass during dietary calcium restriction by altering the Vitamin D endocrine system

CARM1 deficiency inhibits osteoblastic differentiation of bone marrow mesenchymal stem cells and delays osteogenesis in mice

CathepsinKCre mediated deletion of βcatenin results in dramatic loss of bone mass by targeting both osteoclasts and osteoblastic cells

Defective Autophagy in Osteoblasts Induces Endoplasmic Reticulum Stress and Causes Remarkable Bone Loss

Microfibril-Associated Glycoprotein-1, an Extracellular Matrix Regulator of Bone Remodeling

LAMP2A regulates the balance of mesenchymal stem cell adipo-osteogenesis via the Wnt/β-catenin/GSK3β signaling pathway

3118 – CHAPERONE-MEDIATED AUTOPHAGY MAINTAINS LEUKEMIC STEM CELLS

Osteomacs support osteoclast-mediated resorption and contribute to bone pathology in a postmenopausal osteoporosis mouse model

Defective circadian control in mesenchymal cells reduces adult bone mass in mice by promoting osteoclast function